Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced that The University of Alabama’s Culverhouse College of Business will continue its participation in the ai² Pipeline division for the upcoming academic year. The renewed collaboration extends a hands-on program in which students evaluate real-world biopharmaceutical business development and asset assessment opportunities. The program also supports Lōkahi’s strategy of identifying and evaluating promising therapeutic assets that may have been overlooked or are no longer being actively developed.

During its first year, the ai² Futures Lab™ engaged 64 students and identified more than 45 potential assets, several of which advanced into active pipeline discussions. The program expands Lōkahi’s sourcing reach and analytical capacity while supporting a disciplined, capital-efficient approach to pipeline development.